Do persons with chronic myeloid leukaemia have normal or near normal survival?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Do persons with chronic myeloid leukaemia have normal or near normal survival?

Published:2019-12-20 Issue:2 Volume:34 Page:333-335
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Radivoyevitch Tomas,Weaver Davis,Hobbs Brian,Maciejewski Jaroslaw P.,Hehlmann Rudiger,Jiang Qian,Hochhaus Andreas,Gale Robert Peter

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0699-y.pdf

Reference16 articles.

1. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.

2. Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–406.

3. Gambacorti-Passerini C, Antolini L, Mahon, Guilhot F, Deininger M, Fava C, Nagler A, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553–61.

4. Kenzik KM, Bhatia R, Williams GR, Bhatia S. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. Cancer. 2019;125:2570–8.

5. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–8.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of a guaranteed access program to imatinib on the survival of patients with chronic myeloid leukemia;Cancer Causes & Control;2024-09-10

2. Chronic Myeloid Leukemia in Bulgaria in the New Millennium: Identification of Directions for Improvement in Management and Outcomes Reporting;Hemato;2024-08-03

3. Chronic myeloid leukaemia: Biology and therapy;Blood Reviews;2024-05

4. How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen;Leukemia;2024-01-03

5. Precision of diagnostic approaches and individualized therapy toward improving patient outcomes;The New Era of Precision Medicine;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3